• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Exo Therapeutics

  • April 1, 2022
  • New Biotech Startups

Exo Therapeutics leverages its ExoSite™ platform to develop a deep pipeline of potent drug candidates that bind exosites – distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.

Enzymes play key roles in all metabolic processes, such as destroying toxins and aiding digestion. This critical metabolic role can also make enzymes prime culprits in promoting disease states like cancer or inflammation. One way to treat these diseases is to block or modify enzyme activity, however traditional methods to drug enzymes do not work in many cases. 

Exo has built proprietary capabilities for its application in exosite identification and systematized ligand discovery. The company’s ExoSight™ platform leverages a confluence of recent technologies that enable it to see, model, build, design and discover novel exosite-targeted small molecule drugs. Traditional methods of drug discovery have engaged ~7% of the known target space, but with this proprietary platform, the company has identified exosites in classes of enzymes that represent ~30% of the known target space. Exo’s initial focus is in oncology and inflammation, but will expand its therapeutic horizon as development progresses and through strategic partnerships.

Exo Therapeutics was founded in 2020 by Professor David R. Liu, the Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT and Alan Saghatelian at the Salk Institute for Biological Studies. It has raised US$78 million in Series B funding on October 5, 2021. 

Subscribe for alerts on new companies featured on Startups.Bio


September 21, 2023Function Oncology
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring …
July 17, 2023Mallia Therapeutics
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder …
April 21, 2023T-Therapeutics
T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan …
March 26, 2023Empyrean Neuroscience
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.